July 26, 2017
Mergers and Acquisitions
GCA Advises Micro-Macinazione on Its Sale to Lonza
GCA acted as exclusive financial advisor to Cross, the majority shareholder of micronization services provider Micro-Macinazione, on the sale to Lonza, a global supplier to the pharmaceutical, biotech and specialty ingredients markets.
Micro-Macinazione is a contract manufacturer that provides micronization services for the pharmaceutical and fine chemical industries. Micronization is often seen as key to improving the bioavailability of active pharmaceutical ingredients. With improved bioavailability, lower drug doses can be prescribed, potentially reducing a patient’s side effects.
Its acquisition of Micro-Macinazione expands Lonza’s existing clinical and commercial manufacturing capabilities in micronization. Lonza sees micronization as an attractive technology, given its applications across many of the high growth areas of the pharmaceutical market.
Markus Arigoni, CEO of Micro-Macinazione, commented: “By combining with Lonza, we are creating a global leader with the ability to provide customers both in the US and Europe access to the micronization technologies and manufacturing capabilities they need to bring novel drugs to the market faster and more efficiently.”